利拉鲁肽对初诊肥胖2型糖尿病患者成纤维细胞生长因子21和调节性T细胞及血清肝酶的影响

详细信息    查看全文 | 推荐本文 |

英文篇名：Effects of liraglutide on FGF-21,regulatory T cells and serum hepatic enzymes in newly diagnosed obese type 2 diabetes mellitus 作者：卢燕 ; 王晶璞 ; 刘莉红 ; 冯克娜 ; 郑美斯 英文作者：Lu Yan;Wang Jingpu;Liu Lihong;Feng Ke'na;Zheng Meisi;Department of Endocrinology,Baoding Second Hospital; 关键词：糖尿病 ; 2型 ; 肥胖症 ; 利拉鲁肽 ; 成纤维细胞生长因子 ; T淋巴细胞 ; 调节性 英文关键词：Diabetes mellitus,type 2;;Obesity;;Liraglutide;;Fibroblast growth factors;;T-lymphocytes,regulatory 中文刊名：LZBJ 英文刊名：Chinese Journal of Clinical Healthcare 机构：河北保定市第二医院内分泌科;河北保定市第二医院核医学科; 出版日期：2019-07-02 18:49 出版单位：中国临床保健杂志 年：2019 期：v.22 基金：河北省保定市科学研究与发展计划项目(20170254) 语种：中文; 页：LZBJ201904019 页数：4 CN：04 ISSN：34-1273/R 分类号：66-69

摘要

目的探讨分析利拉鲁肽治疗对初诊肥胖2型糖尿病患者成纤维细胞生长因子21(FGF-21)、调节性T细胞及血清肝酶的影响。方法选择门诊诊断的81例初诊肥胖2型糖尿病患者,将其按照随机数字表法分为观察组41例、对照组40例。对照组给予二甲双胍治疗,观察组在对照组基础上给予利拉鲁肽,两组连续治疗16周。比较两组患者治疗前后血糖、体质指数变化情况,血浆FGF-21水平、外周血CD4~+CD25~+Foxp3~+Treg细胞比例以及血清肝酶指标变化。结果两组患者治疗后体质指数及血糖均显著降低(P <0.05),且观察组降低程度更为显著(P <0.05)。治疗后两组患者外周血FGF-21水平、血清肝酶水平均显著降低(P <0.05),且治疗后观察组患者外周血FGF-21水平、血清肝酶水平均显著低于对照组(P <0.05)。治疗后两组患者CD4~+CD25~+Foxp3~+Treg细胞比例较治疗前显著升高(P <0.05),且治疗后观察组患者CD4~+CD25~+Foxp3~+Treg细胞比例显著高于对照组(P <0.05)。结论利拉鲁肽治疗初诊肥胖2型糖尿病可有效降低FGF-21水平、提高调节T细胞比例以及降低血清肝酶水平。
        Objective To investigate the effects of liraglutide on FGF-21,regulatory T cells and serum liver enzymes in newly diagnosed obese type 2 diabetic patients.Methods 81 newly diagnosed obese patients with type 2 diabetes mellitus were randomly divided into observation group(41 cases) and control group(40 cases).The control group was treated with metformin.The observation group was treated with liraglutide on the basis of the control group.The two groups were treated continuously for 16 weeks.The changes of blood glucose,body mass index,plasma FGF-21 level,peripheral blood CD4~+CD25~+Foxp3~+Treg cell ratio and serum hepatic enzyme index were compared between the two groups before and after treatment.Results BMI and blood glucose of the two groups were significantly decreased after treatment(P < 0.05),and the observation group was significantly lower than the control group(P < 0.05).After treatment,the levels of peripheral blood FGF-21 and serum liver enzymes in the two groups were significantly lower than those in the control group(P < 0.05),and the levels of peripheral blood FGF-21 and serum liver enzymes in the observation group were significantly lower than those in the control group(P < 0.05).After treatment,the ratio of CD4~+CD25~+Foxp3~+ Treg cell the two groups was significantly higher than that before treatment(P < 0.05),and the observation group was significantly higher than that of the control group(P < 0.05).Conclusion Liraglutide can effectively decrease level of FGF-21,increase the proportion of T cells and decrease the level of serum liver enzymes.

引文

[1]范世宏,毛玉山.利拉鲁肽联合二甲双胍治疗初诊肥胖2型糖尿病的临床效果分析[J].中国现代医生,2016,54(11):26-28,38.
    [2]贺菲菲,宋民喜,徐琳,等.利拉鲁肽联合基础胰岛素对初诊2型糖尿病合并肥胖患者血糖控制、血脂代谢及氧化应激的影响[J].海南医学院学报,2018,24(2):173-176,180.
    [3]LNNBERG A S,SKOV L,SKYTTHE A,et al.Association of psoriasis with the risk for type 2 diabetes mellitus and obesity[J].Jama Dermatology,2016,152(7):761-767.
    [4]龚敏,王爱华.二甲双胍和瑞舒伐他汀联合用于治疗初诊肥胖型2型糖尿病的疗效观察[J].河北医学,2018,24(2):251-255.
    [5]SHOUKRY A,SHALABY S M,EL-ARABI BDEER S,et al.Circulating serum irisin levels in obesity and type 2 diabetes mellitus[J].Iubmb Life,2016,68(7):544-556.
    [6]贾伟平.中国2型糖尿病防治指南(2017年版)[R].北京:中华医学会糖尿病学分会,2017.
    [7]张伟,马维青,吕芳,等.新诊断2型糖尿病伴腹型肥胖患者胰岛A和B细胞功能与血尿酸的相关性[J].中国临床保健杂志,2017,20(1):61-63.
    [8]胡红琳,王长江.肥胖2型糖尿病患者的治疗[J].中国临床保健杂志,2014,17(1):16-20.
    [9]谢元亮,金朝林,赵湜,等.2型糖尿病初诊患者肝脏脂肪含量的相关因素[J].广东医学,2015,36(5):741-743.
    [10]周书明,尹秋生,曹少军.内脏型肥胖、全身性肥胖与老年糖尿病、糖耐量受损患者之间的关系[J].中国临床保健杂志,2008,11(6):649-650.
    [11]年秀玲,王生力.利拉鲁肽配合健康教育治疗初诊肥胖2型糖尿病的临床观察[J].中国现代医生,2014,52(14):128-129,132.
    [12]陈桂平,王亚非,邢小燕,等.强化运动干预对初诊肥胖2型糖尿病患者体质指数、血糖及血脂的影响[J].中国医刊,2014,49(7):89-90.
    [13]刘新宝,崔艳敏,李喜涛,等.二甲双胍和瑞舒伐他汀联合用于治疗初诊肥胖型2型糖尿病患者时对hsCRP水平的影响[J].河北医药,2015,37(21):3295-3297.
    [14]DE ARAJO I M,SALMON C E,NAHAS A K,et al.Marrow adipose tissue spectrum in obesity and type 2 diabetes mellitus[J].Eur J Endocrinol,2017,176(1):21-30.
    [15]王硕,陈胜武,张晓妍,等.阿卡波糖、二甲双胍联合胰岛素类似物治疗肥胖糖尿病短期疗效[J].医学与哲学,2014,35(3):59-60,65.
    [16]PIETRANI N T,FERREIRA C N,RODRIGUES K F,et al.Proresolving protein Annexin A1:The role in type 2 diabetes mellitus and obesity[J].Biomed Pharmaco Ther,2018,103(11):482-489.
    [17]谭丽艳,齐亚灵,李洪源,等.初诊老年肥胖2型糖尿病患者血清nesfatin-1及apelin水平与胰岛素抵抗的关系[J].中国老年学杂志,2014,34(8):2034-2035.
    [18]潘佳秋,王萌,郭晓闻,等.肥胖对初诊2型糖尿病患者血清β抑制素2及胰岛素抵抗的影响[J].中国全科医学,2014,17(11):1238-1240.
    [19]RIDDY D M,DELERIVE P,SUMMERS R J,et al.G Protein-coupled receptors targeting insulin resistance,obesity,and type 2 diabetes mellitus[J].Pharmacol Rev,2018,70(1):39-67.